The RNA Silencing Group's vision is to achieve a world free of infectious disease using antiviral RNA therapeutics. Our pursuit of antiviral treatments for infectious diseases focuses on developing short interfering (si)RNA therapeutics that potently suppress virus infection.
We are currently developing siRNA targeting a range of viruses that cause chronic disease, such as HIV, HTLV-1, HPV and EBV, or acute respiratory infections, such as SARS-CoV-2 and influenza. Delivery of siRNA therapeutics is another major focus of the group, with multiple innovative nanoparticle platforms being developed and investigated for preclinical antiviral safety and efficacy in relevant mouse models of infection.
